Hledání optimální terapie karotického onemocnění bude zřejmě úkolem i pro další generace lékařů

Josef Veselka

Cor Vasa 2008, 50(9):320-321  

Detecting free plasma DNA in transplant medicine. Possibilities and pitfalls

Jaroslav A. Hubáček, Ivan Málek, Yevgenie Vymětalová, Romana Bohuslavová, Miroslav Kocík

Cor Vasa 2008, 50(9):322-327 | DOI: 10.33678/cor.2008.115  

Aim of study: To evaluate the possibility of detecting free DNA (as a marker of acute rejection) in the plasma of patients after heart transplantation.Methods: Using PCR, different genetic markers were analyzed in the plasma of patients undergoing heart transplantation.Results: Using several genetic markers, we have shown that PCR is not sensitive enough (detecting dilution max ~ 1 : 50) to demonstrate low levels of free plasma DNA of donor origin in cases where forensic markers or diallelic polymorphisms are used. In the tissue of female aortas, Y chromosome-specific DNA was shown to be present in ~ 40% of cases.Conclusions: Given the...

Regression of left ventricular hypertrophy in patients with aortic stent-mounted bioprosthesis implantation

Petr Šantavý, Marián Benčat, Martin Troubil, Pavel Marcián, Petr Němec, Jana Zapletalová, Vladimír Lonský

Cor Vasa 2008, 50(9):328-331 | DOI: 10.33678/cor.2008.116  

Objective: Left ventricular hypertrophy caused by degenerative aortic stenosis should resolve after valve replacement. However, currently implanted stent-mounted bioprostheses do not have fully physiological flow parameters. The purpose of this study was to establish if stent-mounted bioprostheses with suboptimal effective orifice area reduce left ventricle hypertrophy post implantation.Methods: Between March 2002 and December 2006, a total of 293 bioprostheses were implanted at our institution. The bioprostheses used were as follows: Edwards Lifesciences (models 2650, 2900, 3000), Medtronic-Hall (Mosaic), SJM (Epic, Epic Supra), Sorin (More, Soprano)....

Anthracycline-induced cardiomyopathy; an overview of the issue with special emphasis on cardioprotection

Luboš Kraus, Pavel Lovas, Darina Krausová

Cor Vasa 2008, 50(9):332-337 | DOI: 10.33678/cor.2008.117  

Anthracyclines belong to the most active cytotoxic agents for the treatment of a wide variety of solid tumors and hematological malignancies. An undesirable effect associated with chronic administration of anthracyclines is the induction of cardiomyopathy leading to congestive heart failure, usually refractory to common treatments. The issue of anthracycline--induced cardiotoxicity has not been solved to date and current efforts are focused on prevention and new therapeutic strategies. The aim of this overview is to discuss the issue of anthracycline-induced cardiotoxicity in terms of its pathophysiology, risk factors, diagnosis, and current options...

Management of depression or anxiety disorder in coronary heart disease

Milan Vrána, Radkin Honzák

Cor Vasa 2008, 50(9):338-342 | DOI: 10.33678/cor.2008.118  

Depression or anxiety disorder (depression/anxiety) in coronary heart disease (CHD) promotes thrombogenesis, athero-genesis, and arrhythmogenesis. Elimination of depression/anxiety as a risk factor has therefore become a new target of antidepressant therapy in CHD. Pathogenesis-oriented laboratory and clinical trials have shown that the use of selective serotonin reuptake inhibitors (SSRI) paroxetine and sertraline after a previous myocardial infarction and upon CHD compensation reduces the risk for thrombogenesis, atherogenesis, and arrhythmogenesis. Treatment with an antidepressant (paroxetin, sertraline, fluoxetine) likewise reduced cardiovascular...

Arrhythmogenic right ventricular cardiomyopathy and third degree AV block

Jiří Bednář, Jan Václavík, Martin Hutyra, Josef Novotný, Jan Lukl

Cor Vasa 2008, 50(9):343-346 | DOI: 10.33678/cor.2008.119  

This is the case report of a young man with arrhythmogenic right ventricular cardiomyopathy documented by echocardio-graphy and computed tomography. In addition to sustained ventricular tachycardia, third degree AV block was diagnosed with heart failure presentation requiring cardiac pacing. This coincidence of arrhythmias is a rare occurrence in the above condition and has to date been reported only in several isolated cases. Given the recurrent ventricular arrhythmias, the need for cardioversion during the latest attack of malignant arrhythmia and undesirable effects of amiodarone, the patient was indicated for cardioverter/defibrillator implantation.

Variant (Prinzmetal's) angina as a less common cause of cardiac syncope

Marián Fedorco, Tomáš Skála, Jan Václavík, Jan Lukl

Cor Vasa 2008, 50(9):348-351 | DOI: 10.33678/cor.2008.120  

We present the case of a 62-year-old woman admitted for a syncope. During hospitalization, the syncope recurred with new ECG-documented signs of subendocardial ischemia and increased troponin levels, with the episode classified as suspected acute non-ST elevation myocardial infarction. Surprisingly, coronary angiography did not find any significant stenosis. While in a heart center, the patient experienced short episodes of chest tightness with transient junction rhythm, and subsequent anterolateral ST elevation with inferior ST depression. Based on her history, ECG and negative coronary -angiograms, the patient was diagnosed to have variant angina...

Anomální odstup ramus circumflexus z pravého Valsalvova sinu

Jana Mikulová, Josef Veselka, Theodor Adla, Jindřich Charouzek

Cor Vasa 2008, 50(9):352 | DOI: 10.33678/cor.2008.121  

Reimplantace aortální chlopně

Jan Vojáček, Jan Dominik, Martin Tuna, Pavel Žáček, Jan Harrer

Cor Vasa 2008, 50(9):353 | DOI: 10.33678/cor.2008.122  

Treatment of very elderly hypertensives significantly reduces total mortality and the risk of death from stroke. Results of the HYVET trial

Jiří Widimský

Cor Vasa 2008, 50(9):354-357  

Until recently, it was not known whether treatment of hypertension in the very elderly had any beneficial effects. The Hypertension in the Very Elderly Trial (HYVET) is the first prospective, double-blind trial assessing the efficacy of anti-hypertensive therapy in this age group (80 years and older).Overall, 3,845 patients with a mean age of 83.6 years were randomized either to a group receiving active therapy or one receiving placebo. The mean sitting blood pressure prior to therapy initiation was 173.0/90.8 mmHg. Active therapy included indapamide SR at a dose of 1.5mg. Perindopril at doses of 2mg or 4mg could be added to active therapy in cases...

XXV. konference České společnosti pro hypertenzi
XVII. konference pracovní skupiny Preventivní kardiologie ČKS
XIII. konference pracovní skupiny Srdeční selhání ČKS

Cor Vasa 2008, 50(9):K157-173  

Instructions to Authors

Cor Vasa 2008, 50(9):K174-175  

O ctižádostech předsedů II

Cor Vasa 2008, 50(9):K149-150  

Prof. MUDr. Vlastimil Víšek, DrSc., 80 let

Cor Vasa 2008, 50(9):K151  

Zpráva o průběhu a přínosu zahraničního pobytu

Lucie Riedlbauchová

Cor Vasa 2008, 50(9):K152-153  

Přehled vzdělávacích akcí Subkatedry kardiologie IPVZ ve II. pololetí 2008

Cor Vasa 2008, 50(9):K154-155